Insight Molecular Diagnostics (IMDX) Stock Statistics & Valuation Metrics

Insight Molecular Diagnostics has a market cap or net worth of $81.48M. The enterprise value is $200.97M.

Market Cap

$81.48M

Enterprise Value

$200.97M

Insight Molecular Diagnostics has 32,724,285 shares outstanding. The number of shares has decreased by -2.65% in one year.

Shares Outstanding

32,724,285

Owned by Insiders

78.79%

Owned by Institutions

8.03%

Insight Molecular Diagnostics’s return on equity (ROE) is 1.60 and return on invested capital (ROIC) is -197.43%.

Return on Equity (ROE)

1.60

Return on Assets (ROA)

-1.95

Return on Invested Capital (ROIC)

-197.43%

Return on Capital Employed (ROCE)

-2.24

Revenue Per Employee

71.14K

Profits Per Employee

-881.09K

Employee Count

57

Asset Turnover

0.16

Inventory Turnover

8.67

The current PE Ratio of Insight Molecular Diagnostics is -1.64. Insight Molecular Diagnostics’s PEG ratio is -0.02.

PE Ratio

-1.64

PS Ratio

48.99

PB Ratio

-4.31

Price to FCF

-2.65

Price to Operating Cash Flow

-3.41

PEG Ratio

-0.02

In the last 12 months, Insight Molecular Diagnostics had revenue of 4.05M and earned -50.22M in profits. Earnings per share was -1.65.

Revenue

4.05M

Gross Profit

190.00K

Operating Income

-30.58M

Pretax Income

-50.22M

Net Income

-50.22M

EBITDA

-47.92M

Earnings Per Share (EPS)

-1.65

In the last 12 months, operating cash flow was -26.95M and capital expenditures -3.92M, giving a free cash flow of -30.88M billion.

Operating Cash Flow

-26.95M

Free Cash Flow

-30.88M

Free Cash Flow per Share

-0.84

Insight Molecular Diagnostics pays an annual dividend of ―, resulting in a dividend yield of ―

Dividend Per Share

―

Dividend Yield

―

Payout Ratio

N/A

Free Cash Flow Yield

-37.44%

Earnings Yield

-53.30%

Beta

0.96

52-Week Price Change

-61.69%

50-Day Moving Average

3.45

200-Day Moving Average

4.60

Relative Strength Index (RSI)

32.58

Average Volume (3m)

248.63K

Insight Molecular Diagnostics upcoming earnings date is Nov 16, 2026, After Close (Not Confirmed).

Last Earnings Date

Aug 10, 2026

Next Earnings Date

Nov 16, 2026

Ex-Dividend Date

―

Insight Molecular Diagnostics as a current ratio of 1.27, with Debt / Equity ratio of -11.11%

Current Ratio

1.27

Quick Ratio

1.23

Debt to Market Cap

0.00

Net Debt to EBITDA

0.17

Interest Coverage Ratio

-280.53

In the past 12 months, Insight Molecular Diagnostics has paid 0 in taxes.

Income Tax

0

Effective Tax Rate

0.00

Insight Molecular Diagnostics EV to EBITDA ratio is -1.44, with an EV/FCF ratio of -2.18.

EV to Sales

40.32

EV to EBITDA

-1.44

EV to Free Cash Flow

-2.18

EV to Operating Cash Flow

-2.50

Insight Molecular Diagnostics has $17.76M in cash and marketable securities with $2.63M in debt, giving a net cash position of $15.13M billion.

Cash & Marketable Securities

$17.76M

Total Debt

$2.63M

Net Cash

$15.13M

Net Cash Per Share

$0.46

Tangible Book Value Per Share

-$0.58

Gross margin is 11.17%, with operating margin of -2558.74%, and net profit margin of -2955.63%.

Gross Margin

11.17%

Operating Margin

-2558.74%

Pretax Margin

-2955.63%

Net Profit Margin

-2955.63%

EBITDA Margin

-2803.47%

EBIT Margin

-2949.76%

The average price target for Insight Molecular Diagnostics is $9.67, which is 11.43% higher than the current price. The consensus rating is Strong Buy

Price Target

$9.67

Price Target Upside

288.22% Upside

Analyst Consensus

Strong Buy

Analyst Count

4

Revenue Growth Forecast

-60.77%

EPS Growth Forecast

57.26%

Smart Score

7

AI Score

46